Metastatic, unresectable or recurrent cancer should be treated by chemotherapy plus immunotherapy (e.g., nivolumab or pembrolizumab) for HER2-negative, PD-L1 positive tumors, and trastuzumab-based regimens for HER2-positive tumors. The gene discussed is ERBB2; the disease is cancer.